Skip to main content
OpenTrials

Clinical trial condition

PDAC - Pancreatic Ductal Adenocarcinoma

Explore clinical trials studying PDAC - Pancreatic Ductal Adenocarcinoma. Study availability and eligibility vary by location and protocol.

33 public trials 22 recruiting studies
Refine in advanced search Browse all conditions

PDAC - Pancreatic Ductal Adenocarcinoma trial results

Recruiting

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07562152

Conditions
Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +17 more
Locations
  • City of Hope Phoenix, Arizona, United States
  • City of Hope Duarte, California, United States
  • Medical Oncology Hematology Consultants Newark, Delaware, United States
  • Hematology Oncology Associates of the Treasure Coast Port Saint Lucie, Florida, United States
View all 30 locations
View Trial Details
Recruiting

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07491445

Conditions
Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +13 more
Locations
  • Honor Health Research Institute Scottsdale, Arizona, United States
  • H Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View all 20 locations
View Trial Details
Recruiting

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

NCT07621718

Conditions
Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +13 more
Locations
  • Moffitt Cancer Center Tampa, Florida, United States
  • Piedmont Healthcare Atlanta, Georgia, United States
  • University of Chicago Medical Center Chicago, Illinois, United States
  • Johns Hopkins University Baltimore, Maryland, United States
View Trial Details
Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07252232

Conditions
Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +10 more
Locations
  • Cedars-Sinai Cancer at Cedars-Sinai Medical Center Los Angeles, California, United States
  • University of California, Los Angeles Los Angeles, California, United States
  • Stanford Cancer Institute Palo Alto, California, United States
  • University of California, San Francisco San Francisco, California, United States
View all 43 locations
View Trial Details
Recruiting

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

NCT06835569

Conditions
Advanced Solid Tumors, Bronchial Neoplasms, CRC (Colorectal Cancer), +33 more
Locations
  • Research Site Orlando, Florida, United States
  • Research Site Boston, Massachusetts, United States
  • Research Site Boston, Massachusetts, United States
  • Research Site St Louis, Missouri, United States
View Trial Details
Recruiting

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

NCT06917079

Conditions
Advanced Lung Carcinoma, Bronchial Neoplasms, CRC (Colorectal Cancer), +34 more
Locations
  • The Angeles Clinic and Research Institute - West Los Angeles Office Los Angeles, California, United States
  • University of California Davis Sacramento, California, United States
  • University of California San Diego Moores Cancer Center San Diego, California, United States
  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States
View all 17 locations
View Trial Details

Related conditions